PRINCETON, N.J., Sept 17 /PRNewswire-FirstCall/ — Pharmasset,
Inc. (Nasdaq:
VRUS) announces that management will present at the UBS Global
Life Sciences Conference to be held September 20-22, 2010 at the
Grand Hyatt, New York, NY. Schaefer Price, Pharmasset’s President
and Chief Executive Officer, will provide an overview of the
company at the UBS conference on Monday, September 20, 2010 at 9:30
AM (ET).
To access a simultaneous webcast of Mr. Price’s overview via the
internet, log on to the “Events & Presentations” section of the
Investor Center on Pharmasset’s website at http://investor.pharmasset.com/events.cfm.
Please connect to the website at least ten minutes prior to the
start of the presentation to ensure adequate time for a reliable
connection and any software download that may be necessary for the
webcast.
A replay of the webcast will be available on Pharmasset’s
website for thirty days following the conference. The investor
presentation will be available for download in PDF format
immediately following the presentation in the “Events &
Presentations” section of the Investor Center on Pharmasset’s
website at http://investor.pharmasset.com/events.cfm.
About PharmassetPharmasset is a clinical-stage pharmaceutical
company committed to discovering, developing, and commercializing
novel drugs to treat viral infections. Pharmasset’s primary focus
is on the development of oral therapeutics for the treatment of
hepatitis C virus (HCV) and, secondarily, on the development of
Racivir(TM) for the treatment of human immunodeficiency virus
(HIV). Our research and development efforts focus on
nucleoside/tide analogs, a class of compounds which act as
alternative substrates for the viral polymerase, thus inhibiting
viral replication. We curren
‘/>”/>
SOURCE